Hyloris Pharmaceuticals (XBRU:HYL) 3-Year Book Growth Rate : -15.20% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals 3-Year Book Growth Rate?

Hyloris Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €1.40.

During the past 12 months, Hyloris Pharmaceuticals's average Book Value per Share Growth Rate was -27.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was -15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Hyloris Pharmaceuticals was -15.20% per year. The lowest was -15.20% per year. And the median was -15.20% per year.

Competitive Comparison of Hyloris Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Hyloris Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's 3-Year Book Growth Rate falls into.

Hyloris Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Hyloris Pharmaceuticals (XBRU:HYL) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Hyloris Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

0AB6:UK 52U:Germany

Address

Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.